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Background: Heat shock protein (HSP) 47 is a collagen-specific molecular chaperone that is required for molecular
maturation of various types of collagens. We recently reported that HSP47 serum levels were markedly higher in
patients with acute exacerbations of idiopathic pulmonary fibrosis (IPF) when compared with patients with stable
IPF, suggesting that serum HSP47 levels correlate with interstitial pneumonia activity. The aim of this study was to
evaluate serum HSP47 levels in patients with drug-induced lung disease (DILD).
Methods: Findings from high-resolution computed tomographic chest scans of 47 patients with DILD were classified
into one of four predominant patterns: organizing pneumonia (OP) (n = 4), nonspecific interstitial pneumonia (NSIP)
(n = 24), hypersensitivity pneumonitis (HP) (n = 11), and diffuse alveolar damage (DAD) (n = 8). Serum levels of
HSP47, Krebs von den Lungen-6 (KL-6), surfactant protein (SP)-A, and SP-D were measured in these patients.
Results: The PaO2/fraction of inspired oxygen (FiO2) (P/F) ratios were significantly lower and the alveolar-arterial
difference of oxygen (A-a DO2) was significantly higher in the DAD group than in the other groups. Patients with DAD
had the worst outcomes among the different subgroups. Patients in the DAD group had significantly higher serum
HSP47 levels than those in other groups. Receiver operating characteristic curves revealed that HSP47 was superior to
KL-6, SP-A, and SP-D for discriminating between the DAD group and the other groups. The cut-off level for HSP47 that
resulted in the highest diagnostic accuracy was 1711.5 pg/mL. The sensitivity, specificity, and diagnostic accuracy were
87.5%, 97.4%, and 95.7%, respectively. Serum levels of HSP47 in the group of patients requiring glucocorticoids were
significantly higher than those in patients who experienced clinical improvement without glucocorticoid administration.
Serum HSP47 levels also significantly correlated with various respiratory parameters.
Conclusion: This study demonstrated that serum HSP47 levels were elevated in patients with DILD with a DAD pattern
who had the worst outcomes among the different subgroups, and that this was correlated with P/F ratio and A-a DO2.
Keywords: Drug-induced lung disease, Krebs von den Lungen-6, Serum marker, Surfactant protein A, Surfactant
protein DBackground
The increasing use of novel drugs such as tyrosine kinase
inhibitors and disease-modifying anti-rheumatic drugs has
resulted in an increased incidence of drug-induced lung
disease (DILD). While DILD can progress rapidly and
result in fatal outcomes even when the causative drugs are
ceased promptly, there is currently insufficient data to* Correspondence: kakugawa@nagasaki-u.ac.jp
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reproduction in any medium, provided the orhelp guide clinicians in terms of evaluating DILD severity,
identifying patients at high-risk of poor outcomes, and
selecting which patients might benefit from glucocorticoid
administration.
Drugs can induce a variety of pathological reactions in
the lung [1], with patients developing diffuse alveolar dam-
age (DAD) having the worst outcomes. High-resolution
computed tomographic (HRCT) chest scans are currently
the best noninvasive method for predicting the underlying
histologic pattern [1]. In one report, radiographic
appearance was assessed in 70 patients with confirmedtral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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significantly higher in patients with a pattern of extensive
bilateral ground-glass attenuation or airspace consolida-
tions with traction bronchiectasis in HRCT chest scans (a
finding that is thought to reflect DAD) when compared
with patients with other patterns of lung injury [2]. This
finding is consistent with observations by Ichikado et al.,
who reported that traction bronchiectasis is an important
prognostic CT finding in patients with acute interstitial
pneumonia [3]. However, HRCT scanning is expensive,
and the associated radiation exposure is associated with an
increased risk of long-term complications. Therefore, the
identification of other noninvasive markers that specifically
identify DAD and correlate with respiratory status, disease
severity, and outcomes would be of benefit.
A number of serum markers correlate with aspects of
interstitial lung disease, including surfactant protein
(SP)-A, SP-D, and Krebs von den Lungen-6 (KL-6),
which is a circulating high-molecular weight glycoprotein
expressed by type II pneumocytes [4,5]. Previous studies
suggested that KL-6 is a useful diagnostic biomarker for
DILD [6,7]. However, the clinical role of these serum
markers in the diagnosis of DILD remains unclear.
Moreover, there have not been any reports regarding
noninvasive markers that specifically identify DAD and
correlate with respiratory status, disease severity, and














Improved without GC administration (%) 75
Ventilator needed (%) 0
Mortality rate at 30 days (%) 0
Data presented as median (range).
N = number of patients; OP = organizing pneumonia pattern; NSIP = nonspecific inte
diffuse alveolar damage pattern; N.S. = not significant; s/ex/n = current smoker/ex-sm
Disease-modifying anti-rheumatic drugs; NSAIDs = non-steroidal anti-inflammatory d
pared with NSIP group. #; p < 0.01 compared with NSIP group. p < 0.05 comparedHeat shock protein (HSP) 47 is a molecular chaperone
that is required for molecular maturation of various types
of collagens [8-11]. Increased levels of HSP47 in fibrotic
diseases might lead to excessive assembly and intracellular
processing of procollagen molecules, thereby contributing
to the formation of fibrotic lesions [12]. Indeed, studies
have shown that collagen accumulation and disease
progression are associated with HSP47 protein levels in an
experimental pulmonary fibrosis model [13-16]. Previous
studies have also shown a close association between
increased expression of HSP47 in fibrotic lung tissue and
interstitial pneumonia activity [17-19].
We recently reported that HSP47 serum levels were
markedly higher in patients with acute exacerbations of
idiopathic pulmonary fibrosis (IPF) when compared with
patients with stable IPF. Further, serum HSP47 levels are
superior to those of KL-6, SP-A, and SP-D for discriminat-
ing between acute exacerbations of IPF and stable IPF [19].
These findings suggest that serum HSP47 levels correlate
with interstitial pneumonia activity. Therefore, the goal of
this study was to investigate the novel hypothesis that
serum HSP47 might also correlate with DILD status.
Materials and methods
Study population
This was a retrospective study. Study subjects consisted of
47 patients who were admitted to Nagasaki Universitych HRCT pattern
OP NSIP HP DAD P value
(N = 4) (N = 24) (N = 11) (N = 8)
.5 (68-77) 68.0 (34-84) 64.0 (48-79) 69.5 (62-80) N.S.
2 18/6 5/6 5/3 N.S.
/1 2/16/6 0/6/5 3/3/2 N.S.










.0 45.8 36.4 0* 0.05
.0 0.0 0.0 37.5# 0.001
.0 0.0 0.0 37.5# 0.001
rstitial pneumonia pattern; HP = hypersensitivity pneumonitis pattern; DAD =
oker/nonsmoker; HRCT = high-resolution computed tomographic; DMARDs =
rugs; GC = glucocorticoid. *; p < 0.01 compared with OP group. p < 0.05 com-
with HP group.
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were based on a history of drug exposure, radiologic
findings consistent with DILD, and exclusion of other
common causes of pulmonary injury, such as opportunistic
infection, radiation pneumonitis, pulmonary thrombo-
embolism, oxygen administration, and progression of the
primary illness [1,20]. The evidence for lung damage and
exclusion of other causes were obtained by HRCT chest
scanning and other methods including bronchoalveolar
lavage (BAL) (n = 40) and transbronchial lung biopsy (n =
22). The timing of the HRCT chest scanning and BAL was
determined by each attending physician based on the
patients’ status. Sera were obtained at the time of diagnosis
based on these clinical observations and stored at −80°C
for later analysis. Causative drugs were determined accord-
ing to history of drug exposure and response to withdrawal
of the implicated drug, in addition to a lymphocyte stimu-
lation test (n = 28). Data regarding patient characteristics
were collected from clinical notes recorded at the time of
diagnosis and included age, sex, smoking history, PaO2/Table 2 Comparison of various parameters according to each
OP NSIP
(N = 4) (N = 24)
[n]
Hematologic data
WBC (/mm3) 10600 (4300-14600) [4] 6400 (3500-1120
Hb (g/dL) 10.6 (7.9-13.6) [4] 11.7 (8.5-16.2)
Plt (×104/mm3) 25.4 (17.8-31.1) [4] 22.6 (9.7-45.5)
Serum markers
KL-6 (U/mL) 293.0 (144-311) [3] 902.0 (320-3884
SP-A (ng/mL) 48.5 (42.6-54.4) [2] 50.5 (35.9-219)
SP-D (ng/mL) 40.0 (33-169) [3] 193.0 (23-753)
HSP47 (pg/mL) 301.1 (100.5-985.7) [4] 554.4 (61.9-1356
Respiratory parameters [4]
P/F ratio (mmHg) 397.9 (370.9-475.2) 393.8 (260-523.8
A-a DO2 (mmHg) 13.5 (4.3-32.3) 18.9 (−11.3-69.1
BAL fluid findings [4]
Total cell count (× 105/mL) 6.29 (3.6-27.2) 4.66 (1.44-54.9)
Macrophages (%) 57.2 (28.9-73.6) 57.9 (4.6-85.6)
Lymphocytes (%) 29.6 (22.9-52.9) 26.6 (1.7-77.8)
Neutrophils (%) 3.8 (0.6-6.9) 2.5 (0-93.6)
Eosinophils (%) 0.8 (0.5-29.9) 2.7 (0-50.9)
CD4/8 ratio 1.5 (0.36-2.22) 1.8 (0.14-7.5)
Data are presented as medians (range). N = number of patients; n = number of patie
interstitial pneumonia pattern; HP = hypersensitivity pneumonitis pattern; DAD = dif
count; Hb = hemoglobin; Plt = platelet count; KL-6 = Krebs von den Lungen-6; SP-A =
47; P/F ratio = PaO2/fraction of inspired oxygen ratio; A-a DO2 = alveolar-arterial diff
lymphocyte subsets. #; p < 0.01 compared with NSIP and HP group. *; p < 0.01 comp
however, pair-wise comparison by post-hoc analysis did not show any significant dfraction of inspired oxygen (FiO2) ratio (P/F ratio), and
alveolar-arterial difference of oxygen (A-a DO2). Data re-
garding serum concentrations of KL-6, SP-A, and SP-D
were also collected from the clinical notes recorded at the
time of diagnosis. For records that lacked the data for
these markers, measurements were performed using the
preserved serum samples. Data regarding these markers
were not obtained in some patients in which the volume
of preserved serum samples was not sufficient. The
30-day mortality rates were determined for all disease
groups. Sera were also obtained from healthy volunteers
(14 men and 12 women; median age, 31 years; range, 25
to 59 years), all of whom had normal chest radiographs,
were free of symptoms, and were not taking any
medications.
The study protocol was approved by the Institutional
Review Board of Nagasaki University Hospital and the
Ethics Committee, Nagasaki University Graduate School
of Biomedical Sciences. Written informed consent was
obtained from all subjects.HRCT patterns
HP DAD P value
(N = 11) (N = 8)
[n] [n] [n]
0) [23] 6700 (3500-13400) [11] 10450# (4900-20800) [8] 0.01
[23] 12.0 (8.6-14.4) [11] 11.4 (8.6-12.2) [8] N.S.
[23] 26.3 (12.5-33.1) [11] 24.6 (8.9-46.9) [8] N.S.
) [22] 518.5 (264-3697) [10] 442.0 (147-2218) [7] 0.03§
[19] 98.5 (47.1-310) [10] 115.0 (43.4-169) [5] 0.04§
[20] 186.5 (56.2-532) [10] 168.0 (60.0-462) [7] N.S.
) [24] 847.9 (347.7-2012) [11] 1868.3* (816.3-2843.9) [8] <0.001
[21] [11] [8]
) 355.7 (83.1-542.9) 150.7* (71-293.8) <0.001
) 36.3 (−9.5-450.0) 214.8* (42.4-474.7) <0.001
[22] [9] [5]
9.01 (1.8-15.5) 5.28 (1.27-8.9) N.S.
33.8 (4.2-82.7) 32.8 (4.0-94.8) N.S.
54.8 (13.7-95.4) 31.3 (1.9-47) N.S.
3.5 (0-15.8) 32.1 (0.4-52) N.S.
1.6 (0-15.5) 2.0 (0-2.88) N.S.
0.83 (0.14-10.4) 1.08 (0.4-1.4) N.S.
nts examined; OP = organizing pneumonia pattern; NSIP = nonspecific
fuse alveolar damage pattern; N.S. = not significant; WBC = white blood cell
surfactant protein-A; SP-D = surfactant protein-D; HSP47 = heat shock protein
erence of oxygen; BAL = bronchoalveolar lavage; CD4/8 ratio = CD4/CD8 ratio of
ared with OP, NSIP, and HP group. §; Significantly different among the groups;
ifference between any pairs.
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All patients underwent chest radiography and HRCTchest
scanning. The HRCT findings were reviewed separately in
random order by two independent observers who were
not aware of the patients’ profiles and were categorized
into four previously established patterns [1,2,7]: (1) or-
ganizing pneumonia (OP) pattern, showing peribronchial
or subpleural consolidation or ground-glass opacities
without fibrosis; (2) nonspecific interstitial pneumonia
(NSIP) pattern, characterized by patchy or diffuse ground-
glass opacities with associated reticular opacities, traction
bronchiectasis, and bronchiolectasis; (3) hypersensitivity
pneumonitis (HP) pattern, with diffuse ground glass
opacities without fibrosis; and (4) DAD pattern, char-
acterized by extensive bilateral ground glass attenuationTable 3 Comparison of various parameters according to the n
Improved without glucocortico
(N = 18)








Mortality rate at 30 days (%) 0.0
Hematologic data
WBC (/mm3) 6300 (3500-14600)
Hb (g/dL) 12.3 (8.5-14.3)
Plt (×104/mm3) 21.5 (12.5-34.1)
Serum markers
KL-6 (U/mL) 601.0 (264-2115)
SP-A (ng/mL) 52.0 (35.9-141)
SP-D (ng/mL) 158.0 (23-653)
HSP47 (pg/mL) 460.2 (61.9-1631)
Respiratory parameters
P/F ratio (mmHg) 409.0 (260-542.8)
A-a DO2 (mm/Hg) 15.9 (-9.5-69.1)
BAL fluid findings
Total cell count (×105/mL) 4.4 (1.44-15.5)
Macrophages (%) 65.3 (4.3-85.4)
Lymphocytes (%) 26.6 (7.7-95.3)
Neutrophils (%) 3.2 (0-13.6)
Eosinophils (%) 2.1 (0-29.9)
CD4/8 ratio 0.91 (0.14-7.05)
Data are presented as medians (range). HRCT = high-resolution computed tomograpand/or airspace consolidations with traction bronchiec-
tasis and/or traction bronchiolectasis. Following the initial
independent evaluations, divergent observations were
resolved by consensus after consultation between the two
observers.BAL and cell preparation
Bronchoscopy and BAL were performed as described
previously [21].Sandwich enzyme-linked immunosorbent assay (ELISA)
for determination of HSP47 concentration
Sandwich ELISA was performed to determine HSP47
concentration as described previously [22].eed for glucocorticoid administration
id Glucocorticoid needed P value
(N = 29)
[n] [n]
[18] 68.0 (36-80) [29] N.S.
[18] 17/12 [29] N.S.







[18] 7400 (3500-20800) [28] N.S.
[18] 10.9 (7.9-16.2) [28] N.S.
[18] 25.3 (8.9-46.9) [28] N.S.
[16] 531.5 (144-3884) [26] N.S.
[15] 89.8 (43.2-310) [21] 0.02
[15] 175.0 (33-753) [25] N.S.











hic chest scanning. For other abbreviations, see Tables 1 and 2.
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Serum levels of KL-6, SP-A, and SP-D were measured as
described previously [19].
Immunohistochemistry
Immunohistochemistry for HSP47 and type I procollagen
was performed as described previously [17].
Statistical analysis
The interobserver agreement was assessed using
Kappa statistics [23]. Kappa values greater than 0.61
were considered to indicate good agreement between
observers [23]. Continuous variables are expressed as
medians (range). Differences among groups were de-
termined by analysis of variance or by the Kruskal-Table 4 Comparison of various parameters according to survi
Survivors
(N = 44)









WBC (/mm3) 6700.0 (3500-14600)
Hb (g/dL) 11.6 (7.9-16.2)
Plt (×104/mm3) 24.6 (9.7-46.9)
Serum markers
KL-6 (U/mL) 502.0 (144-3884)
SP-A (ng/mL) 64.6 (35.9-310)
SP-D (ng/mL) 168.5 (23-753)
HSP47 (pg/mL) 773.5 (61.9-2500.8)
Respiratory parameters
P/F ratio (mmHg) 372.4 (71-542.8)
A-a DO2 (mmHg) 24.1 (−11.4-474.7)
BAL fluid findings
Total cell count (×105/mL) 5.3 (1.4-54.9)
Macrophages (%) 43.4 (4.0-85.6)
Lymphocytes (%) 34.5 (1.7-95.3)
Neutrophils (%) 3 (0-93.6)
Eosinophils (%) 2 (0-50.8)
CD4/8 ratio 1.42 (0.14-10.4)
Data are presented as medians (range). For abbreviations, see Tables 1, 2, and 3.Wallis test for continuous variables and the χ2 test
for categorical variables, as appropriate. If a signifi-
cant difference was found by analysis of variance, a
pair-wise comparison was performed using the Scheffe
method. Comparisons between two groups were made
using the Wilcoxon two-sample test. Correlations be-
tween variables were assessed using Spearman non-
parametric analysis. The upper left corner coordinate
point of the receiver operating characteristic curve
was used to determine the optimum cutoff level for
discriminating between the DAD group and the other
groups. Statistical analysis was performed using a stat-
istical software package (SAS 9.1.3, SAS Institute,
Cary, NC, USA). A P value <0.05 was considered sta-




[44] 69.0 (62-71) [3] N.S.
[44] 2/1 [3] N.S.






[43] 16500.0 (4900-20800) [3] N.S.
[43] 11.2 (8.6-12.2) [3] N.S.
[43] 16.6 (8.9-40.4) [3] N.S.
[40] 1544.0 (870-2218) [2] N.S.
[34] 65.5 (43.4-87.6) [2] N.S.
[38] 315.0 (168-462) [2] N.S.



























Figure 1 Receiver operating characteristic curve. Based on a
receiver operating characteristic curve, the cut-off level of heat shock
protein (HSP) 47 that resulted in the highest diagnostic accuracy for
drug-induced lung diseases (DILD) with a diffuse alveolar damage
(DAD) pattern was 1711.5 pg/mL. This value discriminated between
the DAD group and the other groups with 87.5% sensitivity and
97.4% specificity and was associated with a diagnostic accuracy of
95.7%. Use of serum HSP47 levels for diagnosis of DILD with a DAD
pattern resulted in the largest area under the curve (0.929) when
compared with the use of serum Krebs von den Lungen-6 (KL-6),
surfactant protein (SP)-A, and SP-D levels (0.367, 0.677, and 0.468,
respectively).
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Interpretation of chest HRCT images
The interobserver variability before reaching consensus
agreement was good (Kappa value = 0.81).
Comparison of various parameters according to HRCT
patterns
Table 1 shows the patient characteristics and categories
of causal drugs among patients according to each HRCT
pattern. There were four patients with the OP pattern,
24 with the NSIP pattern, 11 with the HP pattern, and
eight with the DAD pattern. There were no significant
differences in the duration from HRCT chest scanning
to the serum sample collection and in causal drugs
among the patient groups. In the DAD group, none of
the patients improved without glucocorticoid adminis-
tration, whereas 75.0% (three of four patients) of the OP
group, 45.8% (11 of 24 patients) of the NSIP group, and
36.4% (four of 11 patients) of the HP group improved
without glucocorticoid administration. In the DAD
group, 37.5% of the patients (three of eight patients)
underwent mechanical ventilation, whereas none of the
patients in the other groups required mechanical ventila-
tion. In the DAD group, the 30-day mortality rate was
37.5% (three of eight patients). In contrast, none of the
patients in the other groups died within 30 days.
Table 2 lists laboratory data of the patients according
to each HRCT pattern. Peripheral white blood cell
counts were significantly higher in the DAD group than
in the NSIP and HP groups. Serum HSP47 levels were
significantly higher in the DAD group than in the OP,
NSIP, and HP groups. The P/F ratios were significantly
lower and the A-a DO2 was significantly higher in the
DAD group than in the OP, NSIP, and HP groups. Serum
KL-6 and SP-A levels were significantly different among
the groups, but pair-wise comparison by post-hoc
analysis did not show any significant difference in these
values between any pair of groups. Serum SP-D levels
and BAL fluid findings were not significantly different
among the patient groups. Serum HSP47 levels in the
OP, NSIP, and HP groups did not differ significantly
compared with those in healthy controls (median, 501.6
[range, 149.0-1222.5] pg/mL), while serum HSP47 levels
in the DAD group were significantly higher than those
in healthy controls (P <0.01).
Comparison of various parameters according to the need
for glucocorticoid administration
Eighteen of 47 patients enrolled in this study improved
without glucocorticoid administration. The other 29
patients required glucocorticoid administration. Each
attending physician determined the indication for gluco-
corticoids based on the patient’s status, and these physi-
cians were not aware of the results of serum HSP47 leveltesting. All patients in the DAD group required gluco-
corticoid administration. The P/F ratio was significantly
lower and the A-a DO2 was significantly higher in the
group of patients requiring glucocorticoids when com-
pared with patients that did not require glucocorticoids.
Serum HSP47 and SP-A levels were significantly higher in
the group of patients requiring glucocorticoids when com-
pared with patients that did not require glucocorticoids.
In contrast, there was no difference in serum KL-6 or
SP-D levels or in BAL fluid findings when comparing
the group of patients requiring glucocorticoids with the
patients that did not require glucocorticoids (Table 3).Comparison of various parameters according to survival
at 30 days
All patients who died within 30 days had the DAD pattern
on HRCT. The P/F ratios were significantly lower and the
A-a DO2 was significantly higher in nonsurvivors than in
survivors. Serum HSP47 levels tended to be higher in
nonsurvivors than in survivors, but this difference did not
reach the level of statistical significance (p = 0.08). Serum
KL-6, SP-A, and SP-D levels and BAL fluid findings did
not differ significantly when comparing nonsurvivors and
survivors (Table 4).
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Based on a receiver operating characteristic curve (Figure 1),
the cut-off level of HSP47 that resulted in the highest
diagnostic accuracy for DILD with a DAD pattern was
1711.5 pg/mL. This value discriminated between the DAD
group and the other groups with 87.5% sensitivity and
97.4% specificity and was associated with a diagnostic ac-
curacy of 95.7%. Use of serum HSP47 levels for diagnosis
of DILD with a DAD pattern resulted in the largest area




Figure 2 Correlation between serum heat shock protein (HSP) 47 leve
demonstrated between serum HSP47 levels and (A) PaO2/fraction of inspir
(A-a DO2). Each dot represents a patient with a diffuse alveolar damage (D
nonspecific interstitial pneumonia (NSIP) (quarry), or organizing pneumoniaserum KL-6, SP-A, and SP-D levels (0.367, 0.677, and
0.468, respectively).
Correlations between serum HSP47, KL-6, SP-A, and SP-D
levels and respiratory parameters
A significant correlation was demonstrated between serum
HSP47 levels and the P/F ratio and A-a DO2 (Figure 2).
In contrast, serum KL-6, SP-A, or SP-D levels did not
correlate with the P/F ratio or with A-a DO2 (data not
shown).P = 0.003
r = -0.44
ls and respiratory parameters. Significant correlation was
ed oxygen ratio (P/F ratio) and (B) alveolar-arterial difference of oxygen
AD) (closed circle), hypersensitivity pneumonitis (HP) (open circle),
(OP) (triangle) pattern.
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http://respiratory-research.com/content/14/1/133Histopathological and immunohistochemical findings
Photomicrographs of histological and immunohisto-
chemical studies from representative DAD autopsy spec-
imens are shown in Figure 3. This DAD patient had a
final diagnosis of DILD. The chest HRCT scanning of
this patient at the time of hospitalization revealed a
DAD pattern. The serum HSP47 level was 2843.9 pg/mL
at that time. Histopathological examination revealed
diffuse involvement, including hyaline membranes, inter-
stitial edema and inflammation, and severe fibrosis.
Expression of HSP47 and type I procollagen was diffuse
and high. Expression of HSP47 was noted predominantly
in fibroblasts, epithelial cells, and endothelial cells. Negative
control studies using non-specific immunoglobulin-G
revealed no positive cells (data not shown).
Discussion
This is the first study to investigate the utility of screening
serum HSP47 in the management of DILD. We demon-
strated that serum HSP47 levels were elevated in patients
with DILD with a DAD pattern who had the worst out-
comes among the different subgroups. All patients with a
DAD pattern in HRCT required glucocorticoid admin-
istration, and all patients who underwent mechanical
ventilation or died within 30 days had the DAD pattern
in HRCT. In combination with findings from previous
studies [1,2], the present data suggest that the DAD
pattern in HRCT is an important prognostic factor in
patients with DILD. HSP47 was superior to KL-6, SP-A,
and SP-D for discriminating between the DAD and other
groups. The present study suggested that HSP47 could be
a useful marker to identify patients with DILD with a
DAD pattern. This study also showed that serum HSP47
levels significantly correlated with various respiratory
parameters. In addition, serum levels of HSP47 were sig-
nificantly higher in the group of patients requiring
glucocorticoids than in patients who did not require glu-
cocorticoids. Serum levels of HSP47 also tended to be
higher in nonsurvivors than in survivors. Unlike most
molecular chaperones that recognize a wide variety of
target proteins, the only substrate protein for HSP47 isFigure 3 Histopathological and immunohistochemical findings. Photo
representative diffuse alveolar damage (DAD) autopsy specimens are show
(DILD). Expression of HSP47 was noted predominantly in fibroblasts, epithe
shock protein (HSP) 47. C; type I procollagen. Scale bar = 1 mm.collagen [12]. Hence, the increase of HSP47 might be a
specific reflection of pulmonary fibrotic activity in patients
with DILD. Irrespective of the primary disease, upregula-
tion of HSP47 is a common phenomenon during the
fibrotic process of any organ [8-15,17-19]. Therefore, it is
likely that assessment of serum HSP47 levels might
help to define those patients at risk of developing fibrotic
complications and to monitor the response to treatment.
We previously reported that only a few cells positive
for HSP47 were detected in control lungs, while the
expression of HSP47 was increased in idiopathic usual
interstitial pneumonia specimens [17,24]. However, we
also reported that serum levels of HSP47 did not differ
significantly between patients with stable IPF and
healthy controls [22], while HSP47 serum levels were
markedly elevated in patients with acute exacerbations
of IPF [19]. The present study demonstrated that serum
HSP47 levels were elevated in patients with DILD with a
DAD pattern, while serum HSP47 levels in patients with
other patterns were similar to those in healthy controls.
Taken together, serum HSP47 levels could be elevated
specifically in patients with DAD. Serum HSP47 could
be useful for the specific identification of patients with
DILD with a DAD pattern who are at high risk of poor
outcomes.
We recently reported that the expression of HSP47 in
autopsied DAD lung specimens of patients with acute ex-
acerbation of IPF was greater than that in usual interstitial
pneumonia lung specimens of patients with stable IPF
[19]. The present study also demonstrated that the expres-
sion of HSP47 was also markedly increased in DAD
autopsied lung specimens of patients with DILD. The spe-
cific elevation of serum HSP47 in DILD with a DAD
pattern might be due to not only the strong expression of
HSP47 in lung tissues but also the distinctive characteris-
tics of DAD, including severe inflammation, tissue de-
struction, apoptosis and/or cell necrosis, and increased
vascular permeability [25]. These changes might induce
leakage of HSP47 protein into the peripheral blood.
The histopathologic pattern of DAD is also seen in the
other types of lung injury, such as acute respiratorymicrographs of histological and immunohistochemical studies from
n. This DAD patient had a final diagnosis of drug-induced lung disease
lial cells, and endothelial cells. A; hematoxylin-eosin staining. B; heat
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nective tissue disease-associated interstitial pneumonia,
and so on. It is possible that the expression of HSP47
could be upregulated in DAD lung tissue independent of
the specific disease. Hence, serum HSP47 levels could be
a useful marker for other fatal and rapidly progressive
fibrotic lung diseases that have histological manifestations
similar to those of DAD.
Bronchoscopy with BAL is frequently performed in
patients with DILD. In such patients, BAL fluid cell
counts are usually elevated; lymphocytosis, neutrophilia,
or rarely, eosinophilia may be seen [26]. In this study,
neither the pattern of cellularity nor any other findings
differed when comparing subgroups of patients with
DILD. Therefore, the main role of bronchoscopy in this
context appears to be the exclusion of infection or recur-
rent primary illness.
Treatment for DILD is largely supportive and consists
of immediate causative drug discontinuation, adminis-
tration of supplemental oxygen, empiric antibiotics, and
mechanical ventilation as clinically indicated. Systemic
glucocorticoids are usually recommended, although the
evidence to support their use is largely anecdotal, and
fatalities still occur despite empiric treatment with
high-dose glucocorticoids. HSP47 is involved in the mo-
lecular maturation of collagens, and selective blockade
of HSP47 activity in fibrotic diseases is a potentially
novel therapy. Previous studies in animal models of fi-
brosis (including pulmonary fibrosis) have shown that
down-regulation of HSP47 expression by antisense
oligodeoxynucleotides or by small interfering ribo-
nucleic acid reduces collagen production and subse-
quently diminishes progression of fibrosis [16,27-29].
Thus, downregulation of HSP47 might delay or di-
minish the progression of fibrosis by reducing the ac-
cumulation of collagen. This strategy might be useful
in the management of patients with DILD or other fi-
brotic diseases.
Some limitations to this study should be noted. First, the
number of patients enrolled was small, and pulmonary tox-
icities were caused by many different kinds of drugs. An
analysis of a large number of patients with DILD caused by
a single drug would strengthen the evidence. Moreover, it
should be noted that the number of nonsurvivors (n = 3)
was too small to draw conclusions as to whether HSP47 is
a useful prognostic marker for patients with DILD. Second,
the present study was based on the classification of images
in the absence of pathological evidence. Third, this was a
retrospective study, and the indication for glucocorticoid
administration was determined by attending physicians
who were not aware of the results of serum HSP47 level
testing. Fourth, sequential changes in HSP47 serum levels
after the onset of DILD could not be analyzed due to the
lack of sufficient number of serum stocks. Therefore, it isnot yet clear whether evaluation of these sequential
changes is useful to monitor disease progression and re-
sponse to treatment. A prospective multicenter study with
a larger patient cohort is planned in order to overcome the
above-mentioned limitations of the present study.
Conclusions
In conclusion, this study demonstrated that serum
HSP47 levels were elevated in patients with DILD with a
DAD pattern who had the worst outcomes among the
different subgroups, and that this was correlated with
P/F ratio and A-a DO2. Further studies involving larger
cohorts of patients are warranted to elucidate whether
HSP47 is a useful prognostic marker for patients with
DILD.
Abbreviation
A-a DO2: Alveolar-arterial difference of oxygen; BAL: Bronchoalveolar lavage;
DAD: Diffuse alveolar damage; DILD: Drug-induced lung disease;
ELISA: Enzyme-linked immunosorbent assay; FiO2: Fraction of inspired
oxygen; HP: Hypersensitivity pneumonitis; HRCT: High-resolution computed
tomographic; HSP47: Heat shock protein 47; IPF: Idiopathic pulmonary
fibrosis; KL-6: Krebs von den Lungen-6; NSIP: Nonspecific interstitial
pneumonia; OP: Organizing pneumonia; P/F ratio: PaO2/fraction of inspired
oxygen (FiO2) ratio; SP: Surfactant protein.
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